Working… Menu
Trial record 42 of 115 for:    cancer | butyrate

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02270788
Recruitment Status : Completed
First Posted : October 21, 2014
Last Update Posted : October 3, 2017
Arog Pharmaceuticals, Inc.
Ohio State University
Information provided by (Responsible Party):
St. Jude Children's Research Hospital

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 17, 2016
Actual Study Completion Date : October 17, 2016